Taysha Gene Therapies, Inc. Quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD from Q4 2020 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary
Taysha Gene Therapies, Inc. quarterly Deferred Tax Assets, Operating Loss Carryforwards history and growth rate from Q4 2020 to Q4 2023.
  • Taysha Gene Therapies, Inc. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending December 31, 2023 was $47.4M, a 3.87% increase year-over-year.
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $47.4M +$1.76M +3.87% Dec 31, 2023 10-K 2024-03-19
Q4 2022 $45.6M +$8.6M +23.3% Dec 31, 2022 10-K 2024-03-19
Q4 2021 $37M +$31.2M +537% Dec 31, 2021 10-K 2023-03-28
Q4 2020 $5.81M Dec 31, 2020 10-K 2022-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.